Mar 2, 2026 07:30AM
Mar 2, 2026 07:30AM
Feb 25, 2026 07:57PM
Feb 25, 2026 07:57PM
Feb 24, 2026 04:06PM
Feb 24, 2026 04:05PM
Feb 24, 2026 06:30AM Palvella Therapeutics reports positive phase 3 trial results for rare disease
Feb 24, 2026 06:30AM
Feb 23, 2026 05:00PM
Feb 23, 2026 05:00PM
Feb 2, 2026 07:30AM
Feb 2, 2026 07:30AM
Feb 2, 2026 05:20AM
Jan 9, 2026 07:30AM Palvella plans March 2026 data readout for rare skin disease drug
Jan 9, 2026 07:30AM
Jan 7, 2026 07:30AM
Dec 16, 2025 07:30AM
Dec 16, 2025 07:30AM
Dec 16, 2025 06:09AM
Dec 15, 2025 12:44PM
Dec 15, 2025 08:55AM Raymond James Reiterates Strong Buy Rating on Palvella Therapeutics (PVLA)
Dec 15, 2025 06:00AM
Dec 15, 2025 06:00AM
Dec 5, 2025 06:03AM
Dec 4, 2025 04:41PM
Nov 11, 2025 07:30AM
Nov 6, 2025 07:30AM
Nov 5, 2025 05:31PM Palvella Therapeutics (PVLA) PT Raised to $97 at TD Cowen
Nov 5, 2025 06:00AM
Nov 5, 2025 06:00AM
Nov 4, 2025 07:30AM
Oct 13, 2025 07:30AM
Oct 13, 2025 07:30AM
Sep 26, 2025 06:45AM
Sep 25, 2025 03:12AM Palvella Therapeutics (PVLA) PT Raised to $70 at Jones Trading
Sep 24, 2025 12:41PM
Sep 24, 2025 06:01AM
Sep 24, 2025 06:00AM
Sep 19, 2025 06:50AM
Sep 17, 2025 07:33AM
Sep 17, 2025 07:30AM
Sep 15, 2025 07:30AM Palvella Therapeutics completes enrollment in phase 2 trial for rare skin condition
Sep 15, 2025 07:30AM
Sep 3, 2025 07:31AM
Sep 3, 2025 07:30AM
Aug 28, 2025 07:30AM
Aug 18, 2025 06:48AM
Aug 14, 2025 07:30AM
Aug 7, 2025 07:30AM Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
Aug 5, 2025 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All